Objectives: Annual global deaths from cryptococcal meningitis (CM) are estimated at 180 000 and mortality is as high as 30%, even with optimal therapy. VT-1598 is a novel fungal CYP51 inhibitor with potent intrinsic antifungal activity against Cryptococcus. We report here VT-1598's in vivo antifungal activity in a murine model of CM.
Introduction
Cryptococcal meningitis (CM) has long been recognized as a lifethreatening infection in HIV-infected patients. 1 Unfortunately, although HIV prevalence has decreased with ART, 2 the annual global number of CM deaths remains unacceptably high at an estimated 180 000. 3 Some of this is due to the inability to administer recommended CM induction therapy of amphotericin B plus 5-flucytosine in resource-limited countries (e.g. through lack of access to 5-flucytosine, cost of liposomal amphotericin B and difficulty in administering less expensive but more toxic amphotericin B deoxycholate). 4 Although CM prevalence is much lower in countries with lower HIV burden, CM remains significant due to other causes of immunosuppression such as transplantation and genetic diseases. 5 Additionally, even in settings where recommended therapy is available, the mortality rate is high. For example, in a recent clinical study, 30% of patients given recommended therapy died by day 70. 6 In addition to the high loss of life, morbidity from disease, 7, 8 side effects from treatment, including both toxic effects 9 and drug-drug interactions, 10 and evidence for the possible increase of drug resistance, 11, 12 all encourage the search for better therapies.
As noted, current guidelines recommend that induction treatment is a combination of amphotericin B (preferably delivered in a lipid complex) and 5-flucytosine, given for up to 14 days, followed by a consolidation period of relatively high-dose fluconazole and finally a longer maintenance treatment of a lower dose of fluconazole. 13 These three drugs represent three separate antifungal mechanisms of action and the benefit of combination induction therapy has been clinically proven to be superior to monotherapy. 6 VT-1598 is a novel fungal CYP51 inhibitor that was rationally designed to bind to and inhibit the fungal CYP target with improved selectivity compared with human CYP enzymes. 14, 15 The marked increase in selectivity compared with approved CYP51 inhibitors, such as fluconazole, voriconazole and posaconazole, is largely due to the use of a tetrazole as the haem iron-binding moiety compared with the triazole found in all fungal CYP51 inhibitors developed from the 1980s onward. Because of this improved selectivity, VT-1598 may be devoid of side effects that are due to the inhibition of human CYPs, such as drug-drug interactions 16 and reproductive toxicities. 17, 18 This improved therapeutic index would allow for higher and safer exposures, which could in turn lead to greater efficacy in fungal burden reduction and survival benefit in the treatment of serious invasive infections.
VT-1598 has been shown to have broad potent antifungal coverage in vitro against yeasts, moulds and dimorphic fungi, including the causative agents of CM (Cryptococcus neoformans and Cryptococcus gattii). 19 It has also been reported to have potent in vivo activity against Coccidioides spp. 20 We report here that VT-1598 rapidly equilibrates into brain tissue after oral administration in mice and is highly efficacious in a murine model of CM, both when administered as monotherapy and in combination therapy with liposomal amphotericin B (L-AmB).
Materials and methods

Animals, isolates and drugs
Male CD-1 mice weighing 11-15 g were obtained from Charles River UK (Margate, UK) and were acclimatized for at least 7 days; mean weight of mice at the initiation of each study ranged from 29 to 32 g. Mice were housed in individually ventilated cages with aspen chip bedding, fed and watered ad libitum using standard mouse and rat chow and sterile water in bags. Mice experienced 12 h day-night cycles, $56% relative humidity and temperatures of [20] [21] [22] C. C. neoformans H99 strain was obtained from the ATCC (Rockville, MD, USA). Cultures were maintained on Sabouraud dextrose agar supplemented with 50 mg/L chloramphenicol (SABC) incubated for 72 h at 30 C in aerobic conditions. VT-1598 was supplied by Viamet Pharmaceuticals, Inc. (Durham, NC, USA) either as the free base for in vitro susceptibility assessment or as a tosylate salt for all in vivo studies. A correction factor of 1.3 was used to determine in vivo VT-1598 doses, and all doses reported herein reflect the dose of the free base. L-AmB (in the form of AmBisome) and fluconazole were purchased from Gilead, Cambridge, UK and Genus Pharmaceuticals, Huddersfield, UK, respectively.
In vitro susceptibility
Antifungal susceptibility tests were performed with the C. neoformans H99 strain using a broth microdilution method, with the quality control strain of Candida parapsilosis ATCC 22019, according to CLSI document M27-A3 in Corning #3788 U-well 96-well untreated polystyrene plates using Roswell Park Memorial Institute (RPMI)-1640 broth (Oxoid, UK). A test article concentration range of 0.015-8 mg/L was used. Inoculum preparation, inoculation and incubation of assay plates were all performed according to CLSI guidelines. The incubation temperature was 35 C and results were determined visually following 24, 48 and 72 h. The MIC was defined as the lowest concentration of test articles resulting in either 50% or 100% inhibition of visible growth relative to the positive (drug-free) control. Time-kill studies were conducted with 1 % , 4% and 16 % MIC values of VT-1598 and amphotericin B and fluconazole as controls using C. neoformans H99; cfu were measured at 0, 4, 24 and 48 h.
Pharmacokinetics (PK) and in vitro plasma protein binding
Single-dose oral PK of VT-1598 were determined in healthy (uninfected) mice at TCG Lifesciences Pvt Ltd (Kolkata, India). A dose of 5 mg/kg VT-1598 in 20% Cremophor EL was administered by oral gavage to Swiss albino male mice (n " 3 per timepoint) and plasma and brain tissue concentrations were determined at 0, 0. 
Murine cryptococcal meningitis model
A murine model of cryptococcal meningitis using tail-vein inoculation in immunocompetent mice has been described in the literature. 21 Briefly, yeast extract-peptone-dextrose broth was inoculated 24 h prior to infection with 2-3 isolated colonies of C. neoformans H99 from agar plates and incubated at 37 C. Overnight broths were washed three times with sterile PBS before dilution to the correct inoculum for infection. Mice were inoculated by intravenous injection into the lateral tail vein using $1%10
5 cfu/mouse. For all studies reported, the post-inoculation quantitative counts ranged from 0.7%10 5 to 1.1%10 5 cfu/mouse. Antifungal treatment (n " 10 mice/dose group) was started 24 h after inoculation and continued for 6 days in the short-course fungal burden study and for 14 days in the survival study. Monotherapy treatment groups were given 5, 15 and 50 mg/kg VT-1598 once daily administered by oral gavage, 10 mg/kg L-AmB once daily administered intravenously and 25 mg/kg fluconazole twice daily administered by oral gavage. In the combination study, doses were 2.5 and 5 mg/kg VT-1598 once daily, 7.5 mg/kg L-AmB once daily, 2.5 mg/kg VT-1598/ 7.5 mg/kg L-AmB once daily, 5 mg/kg VT-1598/7.5 mg/kg L-AmB once daily and 25 mg/kg fluconazole twice daily; each drug was administered as above. All studies were performed under UK Home Office Licence 40/3644 and with local ethics committee clearance (The University of Manchester Committee). The mice were monitored at a frequency appropriate for their clinical condition and weights were recorded at least once daily to ensure animals remained within ethical limits.
Brain fungal burden measurements
Fungal burden was determined at the time of sacrifice in brain tissue samples, 24 h after final treatment in the fungal burden studies (8 days after inoculation) or 6 days after the final treatment in the survival study (21 days after inoculation) or when euthanized owing to being moribund. Brains were collected, weighed and homogenized in sterile PBS. Dilutions of the homogenates were prepared and plated onto SABC agar, and the cfu/g was determined after at least 5 days of growth at 30 C.
Drug concentration analyses
Plasma was collected at the same time as brain samples were collected. Compounds were extracted from plasma or brain tissue homogenates with acetonitrile. For PK studies, bioanalyses were performed at TCG Lifesciences Pvt Ltd. For CM efficacy studies, samples were prepared at Evotec, UK and shipped frozen to OpAns, LLC (Durham, NC, USA) for bioanalyses. Each sample was analysed using LC/MS-MS with electrospray ionization, with quantification against an external calibration curve generated in the same matrix and using the signal response ratio between the sample and the internal standard.
Statistical analyses of fungal burden data
Fungal burden and survival data were analysed using StatsDirect software (version 2.7.8). The non-parametric Kruskal-Wallis pairwise comparisons (Conover-Inman) and Mann-Whitney U-tests were used to test all for fungal burden data (P , 0.05 used to indicate significance). Means and Garvey et al.
standard deviations were calculated for plasma and brain concentration data. Survival data were plotted as Kaplan-Meier curves and were analysed using the log-rank test; cfu data were evaluated by the Mann-Whitney U-test.
Results
VT-1598 in vitro antifungal activity against C. neoformans H99
Similar to its activity against a large number of clinical isolates of C. neoformans, 19 VT-1598 potently inhibited the H99 isolate used in the CM model when endpoints were either 50% or 100% inhibition of growth measured up to 72 h (Table 1 ). In the same assay, the MIC values of fluconazole and amphotericin B were in the range reported in the literature against C. neoformans. 22 As expected for a fungal CYP51 inhibitor, 23 VT-1598 was fungistatic in a time-kill study (data not shown). Although it completely suppressed growth of the H99 strain, it failed to reduce viable fungi by .3 log 10 cfu/mL compared with the input level (a maximum decrease of $1.5 log 10 cfu/mL was observed at 16 % MIC at 48 h of incubation). Under the same in vitro conditions and consistent with the literature, 24 amphotericin B was fungicidal (a decrease of .3 log 10 cfu/mL was observed at 1 % MIC at 4 h of incubation) and fluconazole was fungistatic (a maximum decrease of $1.5 log 10 cfu/mL was observed at 4 % MIC at 48 h of incubation).
VT-1598 mouse PK and plasma protein binding VT-1598 was well absorbed in healthy uninfected mice from an oral dose and rapidly penetrated the brain (Figure 1 ). At the earliest timepoint collected (30 min), brain levels were 33% of that measured in plasma. When AUC 0-48 values were compared, VT-1598 brain exposure was 65% of plasma exposure (49 and 76 mgÁh/L for brain and plasma, respectively). Terminal t1 =2 values from both compartments were also similar (16 and 22 h for brain and plasma, respectively). VT-1598 was highly bound to mouse plasma in vitro (.99%). When incubated at either 1 or 5 mg/L, only a very small amount of free VT-1598 was reproducibly measured (,1%).
VT-1598 monotherapy in murine cryptococcal meningitis: a fungal burden study VT-1598 was significantly efficacious in reducing brain fungal burden at all doses tested (Figure 2 ; P , 0.0001 for each dose versus vehicle). The reduction was dose dependent and reached $6 log 10 in the highest dose group, with 2/10 animals showing undetectable viable fungus in the brain. Furthermore, 15 and 50 mg/kg VT-1598 dose treatments significantly reduced brain cfu/g levels compared with the fungal burden measured at the start of treatment (0.89 and 1.43 log 10 reductions, respectively; P , 0.0001 for each dose versus start of treatment). Although both of the positive drug controls also reduced fungal burden compared with vehicle control at the end of the study (P , 0.0001), neither fluconazole nor L-AmB (nor 5 mg/kg VT-1598) reduced brain cfu/g below the level at the start of treatment. VT-1598 plasma levels measured 24 h after the last dose were dose dependent (2.2+0.5, 6.7+1.4 and 17+4 mg/L in the 5, 15 and 50 mg/kg dose groups, respectively). Furthermore, the C 24h level at the 5 mg/kg dose was slightly higher than the corresponding level in the PK study at the same dose (1.5+0.1 mg/L), indicating a slight accumulation upon repeat dosing as expected based on its t1 =2 . The C 24h levels of fluconazole and amphotericin B (from the dose of L-AmB) were 1.5+0.1 and 0.5+0.4 mg/L, respectively, consistent with literature values. 25, 26 The large reduction of fungal burden at a similar dose of VT-1598 was reproduced in an independent fungal burden study (data not shown). When VT-1598 was dosed at 20 mg/kg once daily for 6 days, the mean brain fungal burden measured 1 day after the last dose was 2.89 log 10 cfu/g, which was a 5.26 log 10 reduction compared with vehicle control, and a 0.59 log 10 reduction (P , 0.0001 corrected for multiple comparisons) compared with the cfu/g measured at the start of treatment (3.48 log 10 ). The mean plasma level of VT-1598 measured 1 day after the last dose in the repeat study was 8.2+0.9 mg/L.
VT-1598 monotherapy in murine cryptococcal meningitis: a survival study Vehicle control animals began to succumb to the cryptococcal infection at about day 12 with 60% mortality at the day 21 endpoint (data not shown). All drug-treated animals survived the infection through to the end of the study (two animals died due to gavage errors) and the 90% or 100% treatment survivals were all statistically superior to vehicle (P , 0.016).
Unlike survival, which showed no differentiation between treatment groups, fungal burden determined after a 6 day washout period showed significant differences (Figure 3 ). VT-1598 efficacy was dose-dependent insofar as the low dose was significantly less efficacious than the mid dose (P , 0.0001). However, the small difference between fungal burdens in the 15 mg/kg (mid) and 50 mg/kg (high) doses was not significant, and suggested that the mid dose was at or very close to the maximum-effect dose. The mid and high doses of VT-1598 were significantly superior to both positive drug controls (P , 0.0001) and L-AmB was superior to fluconazole (P " 0.0003). To highlight the effect of a longer drug washout period (6 day versus 1 day), the fungal burden data from the two studies are presented together ( Table 2 ). The small but significant increase of brain cfu/g in the vehicle control group suggests that further expansion of the infection after day 8 is limited due to the onset of mortality. The largest fungal burden expansion was in fluconazole-treated mice and is consistent with its fungistatic activity (i.e. fungus returns to normal growth after drug elimination). There was less expansion in the other treatment groups. VT-1598 efficacy in murine cryptococcal meningitis JAC There were small but significant increases in the VT-1598 5 mg/kg dose and L-AmB groups. However, the very small increases in the VT-1598 15 and 50 mg/kg dose groups were not significant.
Plasma and brain samples collected after the 6 day washout showed little to no drug. There was no consistent drug measured above the lower limit of quantification (LLQ) in any brain sample, demonstrating elimination of drug from the target tissue. Plasma cfu/g brain Figure 2 . VT-1598 displays dose-dependent reduction in brain fungal burden as short-course monotherapy for murine cryptococcal meningitis. Treatment (n " 10 mice/group) began 1 day after inoculation of C. neoformans H99 and lasted for 6 days, with brain samples collected 1 day after the last dose. The pre-treatment control group mice were sacrificed 1 day after inoculation and just prior to start of treatment for other groups. The solid line within each dataset represents the geometric mean of the group and the dotted line represents the LLQ. iv, intravenously; po, per os (orally).
VT-1598 combination therapy in murine cryptococcal meningitis: a fungal burden study
Suboptimal doses of VT-1598 (2.5 and 5 mg/kg) and L-AmB (7.5 mg/kg) were administered as either monotherapies or combinations to probe for possible negative or positive combination effects. Based on the previous fungal burden study (Figure 2 ), all monotherapy treatments behaved as expected (Figure 4) . The four groups in common [pre-treatment (3.34 log 10 cfu/g; data not shown), vehicle, 5 mg/kg VT-1598 and fluconazole] all had mean cfu/g values that were not statistically different between the two studies. As expected, the lower doses of VT-1598 and L-AmB had significantly less reduction in brain fungal burden. In comparing the combination data with the respective monotherapies, there was a positive and significant further reduction in cfu/g in each comparison (P value ,0.0001 for each comparison), with the increases in absolute reduction ranging between 10-and 140-fold in the VT-1598 2.5 mg/kg groups, and 4.8-and 42-fold in the 5 mg/kg groups. Furthermore, the combination of the two CFU/g brain Figure 3 . VT-1598 maintains dose-dependent reduction in brain fungal burden in treating murine cryptococcal meningitis after a 6 day drug washout. Treatment (n " 10 mice/group) began 1 day after inoculation of C. neoformans H99 and lasted for 14 days, with brain samples collected 6 days after the last dose. The solid line within each dataset represents the geometric mean of the group and the dotted line represents the LLQ. Survival was the primary endpoint of this study; therefore, pre-treatment fungal burden was not determined.
VT-1598 efficacy in murine cryptococcal meningitis JAC suboptimal doses of 5 mg/kg VT-1598 and 7.5 mg/kg L-AmB resulted in a fungal burden reduction of 0.65 log 10 compared with the level at the start of treatment.
The plasma and brain levels in the combination study were consistent with the previous PK and efficacy studies ( Table 3) . As previously reported in the literature, 26 amphotericin B was not detected in brain samples. To emphasize, the reduction of brain fungal burden to below that measured at the start of treatment in the 5 mg/kg VT-1598/L-AmB combination group was achieved with relatively low plasma and brain levels of VT-1598 and amphotericin B.
Discussion
CM is an exceedingly large medical concern with an estimated 180 000 deaths globally per year. 3 Most CM occurs in HIV-positive individuals and therefore in countries with high numbers of HIV infections. However, cryptococcal infections occur worldwide, in other immunocompromised settings (e.g. transplantation or genetic deficiencies in the immune system 5 ) and even in immunocompetent individuals. 27 Antifungal treatment of CM is a complex challenge due to the failure rate of recommended therapy (up to 30%) 6 and the lack of access to recommended treatment in those countries most in need. 4 Side effects of the currently used drugs 9,10 and evidence of the emergence of drug resistance 11, 12 add to this daunting challenge. New antifungals that are safe, easily administered and highly efficacious are greatly needed.
VT-1598 was rationally designed to be a more selective fungal CYP51 inhibitor while maintaining high potency. 14, 15 Based on its pre-clinical safety and PK data (E. P. Garvey and R. J. Schotzinger, unpublished data), it has the potential to deliver safe and sustained plasma levels from once-daily oral doses of up to 10-20 mg/L which could be potentially devoid of drug-drug interactions. Its broad intrinsic antifungal activity has been previously reported, 19 including potent activity against the causative agents of CM, C. neoformans and C. gattii. We report here that oral doses of VT-1598 provide robust exposure in both plasma and brain tissue, leading to high in vivo efficacy in a murine model of CM. The dose dependency showed significant differences between low and mid doses, but small and non-significant differences between the mid and high doses, suggesting that the mid dose was near optimal. The mean C 24h plasma level at the mid dose was 6.7 mg/L and, given the 22 h t1 =2 , the C max would therefore be $13 mg/L. Thus, given its pre-clinical profile, a daily steady-state fluctuation between 6 and 13 mg/L upon once-daily administration should be highly efficacious, safe and well-tolerated.
Because of the life-threatening nature of this infection and because of the proven benefit of combination therapy, 6 it would be presumed that the initial clinical investigation of a novel antifungal as a CM treatment would be as a combination induction regimen. Thus, it was important to demonstrate that the combination of VT-1598 and amphotericin B was not antagonistic (and preferably beneficial). The data generated in this study showed that the combination of sub-optimal doses of VT-1598 and L-AmB was beneficial insofar as each combination was superior to its corresponding monotherapies in fungal burden reduction, thus laying the foundation to explore VT-1598/L-AmB combinations in the clinic. CFU/g brain Figure 4 . VT-1598/AmBisome combination increases antifungal efficacy of both monotherapies in treating murine cryptococcal meningitis. Treatment (n " 10 mice/group) began 1 day after inoculation of C. neoformans H99 and lasted for 6 days, with brain samples collected 1 day after the last dose. The solid line within each dataset represents the geometric mean of the group and the dotted line represents the LLQ.
It is well accepted that for any antimicrobial agent the preferred drug not only inhibits growth but kills the pathogen. Thus, amphotericin B's well-documented fungicidal activity explains why it is still widely used in the face of its toxicity profile. In characterizing a fungicidal effect in vitro, there are two classic parameters that are measured:
23 the compound's ability to significantly decrease cfu below the inoculation level in a time-kill kinetic study and to maintain antifungal suppression of growth after drug is removed. The relationship between these in vitro measurements and clinical endpoints such as survival remains unclear. 23 However, it has been proven in clinical studies that the fungicidal amphotericin B has a significantly greater survival benefit than the fungistatic fluconazole in treating CM. 28, 29 We have shown here that VT-1598 is a fungistatic antifungal in vitro in a time-kill study. However, the animal model data indicate that the degree and persistence of fungal burden reduction for VT-1598 was significantly greater than equal or higher daily doses of fluconazole. Additionally, the mid-and high-dose VT-1598 groups displayed fungal burdens significantly below that at the start of treatment, with some animals having undetectable viable fungus in their brain samples. In the face of the same fungistatic in vitro activity for both drugs, the mechanism for this in vivo differentiation is unknown. Regardless, the magnitude of the reduction of brain fungal burden coupled with its prolonged duration provide strong pre-clinical support for clinical studies in treating this devastating disease in humans. VT-1598 efficacy in murine cryptococcal meningitis JAC
